2026/01/27
BEIJING, January 27, 2026 – Co-administration of SINOVAC's Sabin-strain inactivated poliovirus vaccine (sIPV) with either measles-mumps-rubella (MMR) or inactivated hepatitis A (HepA) vaccines is
BEIJING, January 22, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (
2026/01/22
BEIJING, January 20, 2026 – Co-administration of SINOVAC’s live attenuated varicella vaccine (VarV) and trivalent inactivated influenza vaccine (Anflu®) was shown to be safe and immunogenic in in heal
2026/01/20
BEIJING, January 20, 2026 – A large-scale real-world study published in the peer-reviewed journal Vaccines showed that SINOVAC's live attenuated varicella vaccine (VarV) has a stable and favorable
2026/01/20
The content is intended for use by media professionals
These images may be downloaded for non-commercial use and for purposes such as news reporting or research. Images may not be modified and must display the following copyright language: Copyright © SINOVAC Biotech Ltd. All rights reserved.
Learn more about SINOVAC copyright and trademark policies.
Media Contacts: pr@sinovac.com
EN
